452:. Extract the pertinent information rather than just dumping low-level facts in a big list. For example, a long list of side effects is largely useless without some idea of which are common or serious. It can be illuminating to compare the drug with others in its class, or with older and newer drugs. Do not include dose or titration information except when they are extensively discussed by secondary sources, necessary for the discussion in the article, or when listing equivalent doses between different pharmaceuticals. Knowledge is also not an instruction manual or textbook and should not include instructions, advice (legal, medical or otherwise) or "how-to"s (see
95:
1388:
46:
1011:
Include information on the chemical structure, stereochemistry, and chemical composition of the drug (e.g., free base, hydrochloride salt, etc.), physical characteristics, and notable chemical properties. Basic physicochemical properties such as melting pointing, solubility and other raw data should
582:
Where ambiguity exists as to the order in which drugs should be listed, the
British Approved Name for the combination (if one exists) or the order used by the manufacturer of the innovator brand should be used as a guide. For example, although no BAN exists for isosorbide dinitrate/hydralazine above,
925:
of the drug (for example which receptor subtype, ion channel population, isozyme, etc. the drug binds to) and if the drug blocks or activates that target. If relevant, mention what endogenous substance (neurotransmitter, hormone, substrate, etc.) is mimicked or blocked by the drug. Also describe
1045:
When writing about the history of the drug, only include this section if a sufficient amount of information on the drug's origin and/or first synthesis is available. If so, there should be a timeline of first synthesis, approval dates (U.S., Europe, UK, etc.), when marketing stopped or ownership
794:
This section details what forms the drug is available in. Information includes route of administration (e.g. oral, i.v., i.m., rectal, parenteral, intranasal. Oral forms of administration should be differentiated: tablets, crushable tablets, capsules (containing powder, gel, or sprinkle beads),
733:(USAN), development codenames, and the pronunciation -- that content can go in the infobox or the body of the article. In parentheses, list the main or initial brand names for the drug. If there are more than a few brand names, it is best to list these separately in the body of the article.
862:
List the adverse effects (including withdrawal symptoms, if applicable), as well as whether they are common, uncommon, or rare. The latter should only be mentioned if severe or otherwise notable. If possible, use specific statistics (be sure to cite sources!). Use side effect percentage with
721:. If a substance is used primarily as a drug, it should be noted so. Most of our readers access Knowledge on mobile devices, and excess naming becomes clutter that prevents swift access to the heart of the matter. Therefore, avoid cluttering the lead with multiple alternatives to the
484:
states that, "naming should give priority to what the majority of
English speakers would most easily recognize, with a reasonable minimum of ambiguity, while at the same time making linking to those articles easy and second nature." To that end, the World Health Organization
427:
The order of sections used in this guideline is recommended for readability and consistency between articles. The order suggested below is to emphasize information sought after by general readers. If you disagree with part of the style guide, please discuss changes on the
587:
to the chosen name. Non-standard proprietary combination preparations are discouraged, and fall outside the scope of this guideline. For example, a hypothetical "paracetamol/dextromethorphan/pseudoephedrine" page is discouraged and does not fall under this guideline.
771:
This section should go into further detail regarding what the medication is used for (for each major indication). Take special care with regulatory terms; since drug approvals vary from country to country, so does the distinction between approved and
521:, in which case the INN consists of two parts: the cation and the anion name. For example, "chlorphenamine maleate" is the INN modified (INNM) of a common first-generation antihistamine, thus the INN of the active moiety is used as the page title:
716:
without introducing errors or ambiguity. It is also reasonable to have the lead introduce content in the same order as the body of the text. In articles about drugs, they should describe the drug in question, as well as what it does. Note any
603:
Nonproprietary names are common nouns and hence should be lower case except in titles, the beginning of sentences, and in other situations that require capitalization. In contrast, trade names are proper nouns and should always be capitalized.
464:, intended to be read by the lay public so it is important to make technical material as accessible as possible to a wide audience but at the same time, not reducing the value of the article to more technical readers including
1218:
178:
1198:
Look for similar articles to check for what categories they belong to and add the article to any appropriate categories. If no similar articles can be found, add the article to any categories that seem appropriate. See
711:
is defined as "the section before the first headline. The table of contents, if displayed, appears between the lead section and the first headline." The lead of an article, if not the entire article, should be
944:
This section should describe the clinically relevant pharmacokinetic parameters of a drug or active metabolites and the mechanisms of clearance (e.g., specific enzyme systems or transporters). List the
532:
A page should mention other names in the lead section, in boldface, and the naming reference noted if possible. Those other common names of the drug should redirect to that page. For example, the page
1256:
For articles on agents that are primarily recreational in use a section on the "Effects" of the agent early is recommended. This may be followed by sections on "Recreational uses" and "Medical uses".
1363:
1366:
contains an updated list of of articles that don't follow this article title guideline and include the INN in the drugbox INN parameter; these articles are listed under the underscore section.
505:
is more appropriate. For example, "paracetamol" and "acetaminophen" are two common names for the same analgesic, and "paracetamol" is the INN. The relevant
Knowledge article has the page name
143:
226:
745:, but it should be included in every drug-related article. In the source code of the article, it appears before the article lead. It is displayed at the top-right corner of the page. For
1180:
This is not a section — it comes after the last section in the article — but it is nonetheless an important part of any drug article. Most families of drugs already have a template; see
930:
pathways are impacted, what genes are up or down regulated, etc.) and how modulating the activity of the target ultimately translates into the desired therapeutic effect (that is, the
332:
575:("/") character. For example, the standard combination of isosorbide dinitrate and hydralazine, used to treat congestive heart failure in African Americans, is described in the page
1145:
256:
138:
1314:
There is currently no consensus whether codes for drug combinations should be added to articles about single drugs. If you do so, add "(combination with ])" or the like, using the
1149:
155:
33:
308:
429:
210:
1200:
296:
249:
713:
150:
303:
263:
205:
184:
529:. If an INN has yet to be formally listed by WHO, but a proposed INN (pINN) exists, it is considered to be equivalent to the INN with respect to this guideline.
284:
174:
1181:
592:
291:
277:
270:
197:
325:
230:
393:. It contains the articles naming conventions and the general recommended outline of an article, as well as useful information to bring an article to
795:
enteric-coated or slow-release tables/capsules, syrup, sugar-free liquid, or powder (soluble or for suspension). Only include this section if the
192:
119:
784:
dosage information is not recommended as it may be construed as medical advice and be easily subject to vandalism or uninformed good-faith edits.
318:
999:
This section should cover any known drug-microbiota interactions, particularly ones that occur in the gut for orally administered medications.
1399:
934:, for example vasodilation resulting in decreased blood pressure). If the mechanism of action is not known, this section should state that.
613:
501:(INN), also known as recommended International Nonproprietary Name (rINN), if one exists, except in unusual circumstances where another
70:
898:
This section should note what other drugs/food interact with the drug in question, and what effect(s) are produced by this interaction.
390:
114:
100:
17:
1452:
1447:
722:
498:
486:
405:
75:
29:
848:
Under what circumstances should the drug in question not be used? Distinguish relative and absolute contraindications if possible.
650:
Full instructions are available on the page for each infobox. A suitable picture for the infobox is encouraged. For drugs, the 2D
416:(USAN) variant may also be mentioned. The initial brand name(s) follows, in parentheses. All drug names should be in boldface per
576:
698:
Primarily medication-related pages should contain information organized into the following sections, with attention to order.
1024:
646:, the chemical infobox is possibly more appropriate for research drugs for which little or no clinical data is yet available
481:
457:
1208:
730:
1141:
1126:
Avoid the See also section when possible; prefer wikilinks in the main article and navigation templates at the end.
671:
541:
441:
413:
583:
the manufacturer of the innovator brand "BiDil" lists the constituents in that order. Alternative names should be
659:
637:
79:
58:
1136:
These are essential. Unreferenced "information" may be deleted or moved to the talk page. As guidelines we have
679:
655:
552:
551:. All issues of the journal, and lists of all proposed and recommended INNs from 1955 onward, are available in
1204:
954:
950:
556:
1137:
726:
624:
409:
64:
571:, this guideline encourages the use of page titles containing the active constituents separated by the
863:
placebo/control vs. percentage with drug/experimental. Always include adverse events highlighted with
962:
958:
754:
502:
1148:. In short: The popular press is generally not a reliable source for medicine information. See also
1074:
If applicable, describe recreational usage (i.e. abuse) and other illicit usage (for example, using
927:
918:
518:
417:
718:
651:
584:
526:
525:. On the other hand, tiotropium is a quaternary ammonium cation, so the INN used as the title is
346:
1396:
1236:
should be strictly summarized, with clear linking to their main articles for further reading.
1233:
1163:
982:
922:
1228:, the content should primarily focus on what particular effects the combination has, such as
1225:
1057:
738:
568:
54:
1289:
970:
966:
946:
540:, which notes in the first sentence that "salbutamol" is the INN and "albuterol" is the
1079:
931:
708:
662:
is acceptable. The easiest way to populate the drugbox and protein templates is to use
522:
465:
162:
1441:
1358:
1350:
1075:
877:
This section describes symptoms of overdose, what to do in case of overdose, and the
864:
773:
758:
510:
453:
1296:
1279:
1229:
1185:
663:
513:. If a compound exists in salt form, then the INN is the name of the active moiety
461:
398:
394:
237:
1354:
1268:
643:
630:
506:
1393:
Scientific Style and Format: the CBE Manual for
Authors, Editors and Publishers
94:
1346:
1245:
537:
469:
421:
386:
1108:
Ongoing investigations into a medication that have not reached clinical usage
1342:
1150:
Knowledge:Manual of Style (medicine-related articles)#Citing medical sources
533:
1361:, which redirect to an article title that differs from the INN listed here.
67:
on how to format and present article content within their area of interest.
1219:
Knowledge talk:WikiProject
Pharmacology/General/Main sections of drug page
1088:
Global sales, distribution, cost in major
English speaking countries, etc.
776:. A more detailed description of drug regulation should go to the section
404:
The article title and the first name to mention in the lead should be the
89:
1264:
746:
460:). Finally it is important to keep in mind that we are writing a general
986:
978:
974:
567:
Since no international convention exists to guide naming of standard
1211:
for templates to choose from. Language links go right to the bottom.
1271:
should be added to the drugbox. If there is more than one, use the
547:
INNs are published by the World Health
Organization in the journal
572:
878:
809:
Include one or more of the following subsections if appropriate:
382:
45:
1295:. This ensures proper linking of the codes – to the ATC lists (
690:
The ordering of section may vary depending on the article type
593:
Knowledge:WikiProject
Pharmacology/Workspace#Naming conventions
1300:
40:
1364:
Category:Infobox drug articles with non-default infobox title
1068:
Describe regulatory status in different regions of the world.
989:). Some of this information is also included in the drugbox.
926:
the downstream consequences of modulating that target (what
675:
93:
1094:
Brand names of the medication and manufacturer, if notable.
667:
618:
Infoboxes should be used where appropriate. These include
389:
articles on
Knowledge, as established by the consensus of
1162:
Avoid this section if possible, since it is a magnet for
449:
445:
1188:
for an immunosuppressant) for which template(s) to use.
368:
361:
354:
1146:
Knowledge:Reliable sources (medicine-related articles)
1395:(6th ed.). Cambridge: Cambridge Univ. Press. p. 324.
1116:
If different from use in humans or otherwise notable.
1100:
Controversies surrounding the medication, if notable.
34:
Knowledge:Manual of Style (medicine-related articles)
1207:, if applicable, goes below the category links. See
799:
field of the drugbox does not provide enough space.
489:(INN) should normally be used as the article name.
440:Try to avoid cloning drug formularies such as the
63:It contains the advice or opinions of one or more
1303:database. Recommended sorting of multiple codes:
1201:Knowledge:WikiProject Pharmacology/Categorization
497:A drug article should be titled according to its
591:Tasks related to this guideline can be found at
1321:Drugs without an ATC(vet) code should have set
973:and the major metabolizing enzymes for example
326:
8:
1310:Within these two groups, sort alphabetically
1182:Knowledge:WikiProject Pharmacology/Templates
1431:, and may also be found in the page's URL.
424:and family and the main therapeutic uses.
333:
319:
884:(median lethal dose), if it is available.
1166:. Links to on-line pharmacies and blogs
1389:"Chaper 19: Drugs and Pharmacokinetics"
1379:
1334:
1020:(only necessary for articles tagged by
753:. More information can be found at the
1275:parameter together with the templates
1244:Add a section listing "Agents" in the
1418:, and may be found in the page's URL.
7:
1184:and the appropriate ATC list (e. g.
678:for the protein and enter the ID in
1387:CBE Style Manual Committee (2002).
614:Knowledge:Manual of Style/Infoboxes
1056:Don't use this section for adding
750:
666:template-filling web site. Search
408:(INN) of the drug; see below. The
391:Knowledge:WikiProject Pharmacology
80:thoroughly vetted by the community
24:
18:Knowledge:WikiProject Pharmacology
1203:for categories to choose from. A
965:, major metabolic pathways (e.g.
917:If known, describe the molecular
670:for the drug and enter the ID in
499:International Nonproprietary Name
487:International Nonproprietary Name
406:International Nonproprietary Name
577:Isosorbide dinitrate/hydralazine
44:
1414:DrugBank IDs follow the format
1:
1307:ATC codes before ATCvet codes
1194:Categories and language links
714:written as simply as possible
76:Knowledge policy or guideline
458:Knowledge:Medical disclaimer
1427:HUGO IDs follow the format
1341:Notable exceptions include
1209:Category:Pharmacology stubs
1078:to facilitate robbery/as a
865:mandated prominent warnings
731:United States Approved Name
1469:
1142:Knowledge:Reliable sources
761:is able to provide images.
611:
563:Standard combination drugs
542:United States Adopted Name
444:and online resources like
414:United States Adopted Name
344:
1232:. Regular effects of the
1012:be placed in the drugbox.
658:format is preferred, but
243:
220:
165:
161:
108:
92:
1453:WikiProject Pharmacology
1448:WikiProject style advice
1299:etc.) as well as to the
1221:for related discussion.
1034:Detection in body fluids
797:Routes of administration
921:including the specific
1176:Navigational templates
951:volume of distribution
755:template documentation
741:This is not a section
536:redirects to the page
436:General considerations
227:Requested articles (1)
98:
1138:Knowledge:Attribution
1025:WikiProject Chemicals
727:British Approved Name
612:Further information:
410:British Approved Name
381:for the structure of
292:Resources for editors
97:
78:, as it has not been
995:Pharmacomicrobiomics
805:Specific populations
549:WHO Drug Information
509:, and a redirect at
480:Knowledge policy on
109:General information
1252:Recreational agents
1052:Society and culture
928:signal transduction
919:mechanism of action
909:Mechanism of action
519:quaternary compound
493:Articles to use INN
1234:active ingredients
820:Labor and delivery
725:name, such as the
719:black box warnings
527:Tiotropium bromide
472:, and scientists.
257:Structure diagrams
99:
1401:978-0-521-47154-1
1323:ATC_prefix = none
1226:combination drugs
1046:transferred, etc.
983:monoamine oxidase
923:biological target
890:Drug interactions
844:Contraindications
569:combination drugs
482:naming convention
343:
342:
216:
215:
88:
87:
1460:
1432:
1430:
1425:
1419:
1417:
1412:
1406:
1405:
1384:
1367:
1339:
1324:
1317:
1316:ATC_supplemental
1294:
1288:
1284:
1278:
1274:
1273:ATC_supplemental
1072:Recreational use
1029:
1023:
940:Pharmacokinetics
913:Pharmacodynamics
780:, further down.
641:
638:Infobox chemical
628:
399:featured article
371:
364:
357:
335:
328:
321:
163:
139:Reliable sources
90:
74:is not a formal
71:This information
48:
41:
1468:
1467:
1463:
1462:
1461:
1459:
1458:
1457:
1438:
1437:
1436:
1435:
1428:
1426:
1422:
1415:
1413:
1409:
1402:
1386:
1385:
1381:
1376:
1371:
1370:
1340:
1336:
1331:
1322:
1315:
1292:
1286:
1282:
1276:
1272:
1262:
1254:
1242:
1060:to the article.
1027:
1021:
955:protein binding
947:bioavailability
882:
854:Adverse effects
790:Available forms
696:
688:
635:
622:
616:
610:
601:
565:
495:
478:
466:medical doctors
438:
420:. Indicate the
375:
374:
367:
360:
353:
349:
339:
206:Editor outreach
127:Manual of Style
84:
83:
28:For the parent
22:
21:
20:
12:
11:
5:
1466:
1464:
1456:
1455:
1450:
1440:
1439:
1434:
1433:
1420:
1407:
1400:
1378:
1377:
1375:
1372:
1369:
1368:
1362:
1333:
1332:
1330:
1327:
1312:
1311:
1308:
1261:
1258:
1253:
1250:
1241:
1238:
1215:
1214:
1213:
1212:
1191:
1190:
1189:
1173:
1172:
1171:
1158:External links
1155:
1154:
1153:
1129:
1128:
1127:
1119:
1118:
1117:
1112:Veterinary use
1109:
1103:
1102:
1101:
1095:
1089:
1083:
1080:date rape drug
1069:
1062:
1061:
1049:
1048:
1047:
1038:
1037:
1036:
1031:
1014:
1013:
1004:
1003:
1002:
1001:
1000:
992:
991:
990:
937:
936:
935:
932:mode of action
901:
900:
899:
887:
886:
885:
880:
870:
869:
868:
851:
850:
849:
841:
840:
839:
838:
837:
835:In the elderly
832:
827:
822:
817:
811:
810:
802:
801:
800:
786:
785:
774:off-label uses
764:
763:
762:
735:
734:
695:
692:
687:
684:
648:
647:
642:– for example
633:
629:– for example
609:
606:
600:
599:Capitalization
597:
564:
561:
523:Chlorphenamine
494:
491:
477:
474:
437:
434:
373:
372:
365:
358:
350:
345:
341:
340:
338:
337:
330:
323:
315:
312:
311:
306:
300:
299:
294:
288:
287:
281:
280:
274:
273:
267:
266:
260:
259:
253:
252:
250:Categorization
246:
245:
244:Other content
241:
240:
234:
233:
223:
222:
218:
217:
214:
213:
208:
201:
200:
195:
188:
187:
182:
170:
169:
159:
158:
153:
147:
146:
141:
135:
134:
129:
123:
122:
117:
111:
110:
106:
105:
102:
86:
85:
68:
51:
49:
39:
38:
23:
15:
14:
13:
10:
9:
6:
4:
3:
2:
1465:
1454:
1451:
1449:
1446:
1445:
1443:
1424:
1421:
1411:
1408:
1403:
1398:
1394:
1390:
1383:
1380:
1373:
1365:
1360:
1359:tenamfetamine
1356:
1352:
1351:metamfetamine
1348:
1344:
1338:
1335:
1328:
1326:
1319:
1309:
1306:
1305:
1304:
1302:
1298:
1291:
1281:
1270:
1266:
1259:
1257:
1251:
1249:
1247:
1239:
1237:
1235:
1231:
1227:
1222:
1220:
1210:
1206:
1205:stub template
1202:
1197:
1196:
1195:
1192:
1187:
1183:
1179:
1178:
1177:
1174:
1169:
1165:
1161:
1160:
1159:
1156:
1151:
1147:
1143:
1139:
1135:
1134:
1133:
1130:
1125:
1124:
1123:
1120:
1115:
1114:
1113:
1110:
1107:
1104:
1099:
1098:Controversies
1096:
1093:
1090:
1087:
1084:
1081:
1077:
1076:flunitrazepam
1073:
1070:
1067:
1064:
1063:
1059:
1055:
1054:
1053:
1050:
1044:
1043:
1042:
1039:
1035:
1032:
1026:
1019:
1016:
1015:
1010:
1009:
1008:
1005:
998:
997:
996:
993:
988:
984:
980:
976:
972:
968:
964:
960:
956:
952:
948:
943:
942:
941:
938:
933:
929:
924:
920:
916:
915:
914:
910:
907:
906:
905:
902:
897:
896:
895:
891:
888:
883:
876:
875:
874:
871:
866:
861:
860:
859:
855:
852:
847:
846:
845:
842:
836:
833:
831:
828:
826:
823:
821:
818:
816:
813:
812:
808:
807:
806:
803:
798:
793:
792:
791:
788:
787:
783:
779:
775:
770:
769:
768:
765:
760:
759:User:Fuzzform
756:
752:
748:
744:
740:
737:
736:
732:
728:
724:
720:
715:
710:
706:
705:
704:
701:
700:
699:
693:
691:
685:
683:
681:
677:
673:
669:
665:
661:
657:
653:
645:
639:
634:
632:
626:
621:
620:
619:
615:
607:
605:
598:
596:
594:
589:
586:
580:
578:
574:
570:
562:
560:
558:
554:
550:
545:
543:
539:
535:
530:
528:
524:
520:
516:
512:
511:Acetaminophen
508:
504:
500:
492:
490:
488:
483:
475:
473:
471:
467:
463:
459:
455:
451:
447:
443:
435:
433:
431:
425:
423:
419:
415:
411:
407:
402:
400:
396:
392:
388:
384:
380:
370:
366:
363:
359:
356:
352:
351:
348:
336:
331:
329:
324:
322:
317:
316:
314:
313:
310:
307:
305:
302:
301:
298:
295:
293:
290:
289:
286:
283:
282:
279:
276:
275:
272:
269:
268:
265:
262:
261:
258:
255:
254:
251:
248:
247:
242:
239:
236:
235:
232:
228:
225:
224:
219:
212:
209:
207:
203:
202:
199:
196:
194:
190:
189:
186:
183:
180:
176:
172:
171:
168:
164:
160:
157:
154:
152:
151:Popular pages
149:
148:
145:
142:
140:
137:
136:
133:
130:
128:
125:
124:
121:
118:
116:
113:
112:
107:
104:
96:
91:
81:
77:
73:
72:
66:
62:
60:
56:
50:
47:
43:
42:
37:
35:
31:
26:
25:
19:
1429:hgnc_id=xxxx
1423:
1410:
1392:
1382:
1337:
1320:
1313:
1297:ATC code A01
1269:ATCvet codes
1263:
1255:
1243:
1240:Drug classes
1230:drug synergy
1223:
1216:
1193:
1186:ATC code L04
1175:
1167:
1157:
1131:
1121:
1111:
1105:
1097:
1091:
1085:
1071:
1066:Legal status
1065:
1051:
1040:
1033:
1017:
1006:
994:
939:
912:
908:
904:Pharmacology
903:
894:Interactions
893:
889:
872:
858:Side effects
857:
853:
843:
834:
829:
824:
819:
814:
804:
796:
789:
781:
778:Legal status
777:
767:Medical uses
766:
742:
709:lead section
702:
697:
689:
674:, or search
649:
625:Infobox drug
617:
602:
590:
581:
566:
548:
546:
531:
514:
496:
479:
476:Article name
462:encyclopedia
454:WP:NOT#HOWTO
439:
426:
418:WP:BOLDTITLE
403:
395:good article
378:
376:
362:WP:DRUGGUIDE
304:Participants
238:Cleanup list
221:How to help
166:
131:
126:
115:Project page
103:Pharmacology
69:
65:WikiProjects
52:
27:
1355:diamorphine
1318:parameter.
1217:Please see
1170:be deleted.
1092:Brand names
830:In children
694:Medications
644:ICI-118,551
631:Paracetamol
557:WHO website
507:Paracetamol
503:common name
470:pharmacists
379:advice page
377:This is an
369:WP:PHARMMOS
355:WP:DRUGLIKE
264:Photographs
167:Departments
101:WikiProject
53:This is an
1442:Categories
1374:References
1347:amfetamine
1132:References
585:redirected
538:Salbutamol
422:drug class
387:medication
285:Historical
175:Assessment
1416:APRDxxxxx
1343:lysergide
1265:ATC codes
1260:ATC codes
1086:Economics
1058:WP:TRIVIA
1018:Synthesis
1007:Chemistry
963:clearance
959:half-life
825:Lactation
815:Pregnancy
747:ATC codes
729:(BAN) or
680:this page
672:this page
664:Diberri's
652:structure
608:Infoboxes
534:Albuterol
450:Drugs.com
430:talk page
412:(BAN) or
347:Shortcuts
278:Workspace
271:Templates
30:guideline
1122:See also
1106:Research
971:phase II
873:Overdose
782:Detailed
686:Sections
668:DrugBank
544:(USAN).
517:it is a
456:and the
401:status.
193:Research
1041:History
969:and/or
967:phase I
739:Drugbox
555:on the
1357:, and
1290:ATCvet
987:UGT2B7
979:CYP3A4
975:CYP2D6
749:, see
743:per se
515:unless
446:RxList
32:, see
1329:Notes
1246:class
751:below
573:slash
59:style
55:essay
16:<
1397:ISBN
1285:and
1267:and
1224:For
1168:will
1164:spam
1144:and
707:The
703:Lead
676:HUGO
448:and
385:and
383:drug
309:talk
297:talk
211:talk
198:talk
185:talk
156:talk
144:talk
132:talk
120:talk
1301:WHO
1280:ATC
911:or
892:or
856:or
723:INN
660:PNG
656:SVG
654:in
553:PDF
442:BNF
397:or
231:(2)
179:Log
57:on
1444::
1391:.
1353:,
1349:,
1345:,
1325:.
1293:}}
1287:{{
1283:}}
1277:{{
1248:.
1140:,
1082:).
1028:}}
1022:{{
985:,
981:,
977:,
961:,
957:,
953:,
949:,
881:50
879:LD
757:.
682:.
640:}}
636:{{
627:}}
623:{{
595:.
579:.
559:.
468:,
432:.
229:/
204:→
191:→
181:)
173:→
1404:.
1152:.
1030:)
867:.
334:e
327:t
320:v
177:(
82:.
61:.
36:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
